6-(4-(6-((6-acetyl-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)hexanamide

ID: ALA4455429

PubChem CID: 155524698

Max Phase: Preclinical

Molecular Formula: C43H48N10O7

Molecular Weight: 816.92

Molecule Type: Unknown

This compound is available for customization.

Associated Items:

Bioactivity Summary Target Summary Assay Summary

Names and Identifiers

Canonical SMILES: CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCN(CCCCCC(=O)Nc5cccc6c5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)cn3)nc2n(C2CCCC2)c1=O

Standard InChI: InChI=1S/C43H48N10O7/c1-25-30-24-45-43(49-38(30)52(27-9-5-6-10-27)41(59)36(25)26(2)54)47-33-16-14-28(23-44-33)51-21-19-50(20-22-51)18-7-3-4-13-34(55)46-31-12-8-11-29-37(31)42(60)53(40(29)58)32-15-17-35(56)48-39(32)57/h8,11-12,14,16,23-24,27,32H,3-7,9-10,13,15,17-22H2,1-2H3,(H,46,55)(H,48,56,57)(H,44,45,47,49)

Standard InChI Key: HJEZCPKGRBNZSZ-UHFFFAOYSA-N

Molfile:

 
     RDKit          2D

 60 67  0  0  0  0  0  0  0  0999 V2000
   35.7664   -1.8273    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   36.5067   -2.1916    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   37.9859   -2.9174    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   37.9281   -2.0900    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   37.1884   -1.7297    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   37.2994   -3.3765    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   36.5635   -3.0091    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.9866   -3.5953    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   36.3659   -4.3252    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   37.1772   -4.1899    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.1707   -3.4730    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   37.7654   -4.7685    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   35.9987   -5.0590    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.1742   -5.1070    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.8055   -5.8410    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.2571   -6.5319    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   36.0817   -6.4839    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   36.4546   -5.7450    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   37.2783   -5.6960    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   34.8857   -7.2687    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   25.0587   -4.7153    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   25.7751   -4.3019    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.7723   -3.4714    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   25.0569   -3.0623    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.3438   -4.3024    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.3479   -3.4795    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.6413   -3.0669    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.9261   -3.4725    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.9219   -4.2954    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.6331   -4.7126    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   23.6466   -2.2419    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.2142   -3.0554    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.2195   -2.2304    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   21.4971   -3.4634    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.2050   -4.7035    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   23.6331   -5.5410    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.9639   -6.0236    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.2160   -6.8091    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.0411   -6.8121    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.2988   -6.0284    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.4903   -4.7133    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   27.2042   -4.2997    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.9159   -4.7115    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.6293   -4.2986    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.6284   -3.4727    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.9082   -3.0615    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.1978   -3.4768    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   29.3361   -3.0592    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   30.0517   -3.4719    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.7628   -3.0608    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.7646   -2.2355    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   30.0492   -1.8228    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.3317   -2.2356    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.4795   -1.8236    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.1936   -2.2367    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.9085   -1.8248    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.6227   -2.2380    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.3374   -1.8261    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.0516   -2.2392    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.0509   -3.0643    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  7  2  0
  6  3  2  0
  3  4  1  0
  4  5  2  0
  5  2  1  0
  6  7  1  0
  7  8  1  0
  8  9  1  0
  9 10  1  0
 10  6  1  0
  8 11  2  0
 10 12  2  0
 13 14  1  0
 13 18  1  0
 14 15  1  0
 15 16  1  0
 16 17  1  0
 17 18  1  0
  9 13  1  0
 18 19  2  0
 16 20  2  0
 25 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 26  1  0
 25 26  2  0
 25 30  1  0
 26 27  1  0
 27 28  2  0
 28 29  1  0
 29 30  1  0
 27 31  1  0
 28 32  1  0
 32 33  2  0
 32 34  1  0
 29 35  2  0
 36 37  1  0
 37 38  1  0
 38 39  1  0
 39 40  1  0
 40 36  1  0
 30 36  1  0
 22 41  1  0
 41 42  1  0
 42 43  2  0
 43 44  1  0
 44 45  2  0
 45 46  1  0
 46 47  2  0
 47 42  1  0
 48 49  1  0
 48 53  1  0
 49 50  1  0
 50 51  1  0
 51 52  1  0
 52 53  1  0
 45 48  1  0
 51 54  1  0
 54 55  1  0
 55 56  1  0
 56 57  1  0
 57 58  1  0
 58 59  1  0
 59  1  1  0
 59 60  2  0
M  END

Associated Targets(Human)

CDK4 Tclin Protein cereblon/Cyclin-dependent kinase 4 (68 Activities)

Discover Target: CDK4

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CDK6 Tclin Protein cereblon/Cyclin-dependent kinase 6 (113 Activities)

Discover Target: CDK6

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Natural Product: No	Oral: No	Chemical Probe: No	Parenteral: No
Molecule Type: Unknown	Topical: No	First In Class: No	Black Box: No
Chirality: No	Availability: No	Prodrug: No

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 816.92	Molecular Weight (Monoisotopic): 816.3707	AlogP: 4.28	#Rotatable Bonds: 13
Polar Surface Area: 208.90	Molecular Species: NEUTRAL	HBA: 14	HBD: 3
#RO5 Violations: 2	HBA (Lipinski): 17	HBD (Lipinski): 3	#RO5 Violations (Lipinski): 2
CX Acidic pKa: 11.14	CX Basic pKa: 8.34	CX LogP: 4.17	CX LogD: 3.19
Aromatic Rings: 4	Heavy Atoms: 60	QED Weighted: 0.10	Np Likeness Score: -1.00

References

1. Rana S, Bendjennat M, Kour S, King HM, Kizhake S, Zahid M, Natarajan A.. (2019) Selective degradation of CDK6 by a palbociclib based PROTAC., 29 (11): [PMID:30935795] [10.1016/j.bmcl.2019.03.035]
2. Gray, N S NS and 12 more authors. 1998-07-24 Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. [PMID:9677190]
3. Kubo, A A and 9 more authors. 1999-12 The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4. [PMID:10632371]
4. Soni, R R and 7 more authors. 2000-09-07 Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product. [PMID:10973815]
5. Lane, M E ME and 9 more authors. 2001-08-15 A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. [PMID:11507069]
6. Tavares, Francis X FX and 7 more authors. 2004-09-09 N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy. [PMID:15341487]
7. Fry, David W DW and 10 more authors. 2004-11 Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. [PMID:15542782]
8. Pennati, Marzia M and 12 more authors. 2005-09 Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. [PMID:16170024]
9. Sridhar, Jayalakshmi J, Akula, Nagaraju N and Pattabiraman, Nagarajan N. 2006-03-24 Selectivity and potency of cyclin-dependent kinase inhibitors. [PMID:16584130]
10. DePinto, Wanda W and 19 more authors. 2006-11 In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials. [PMID:17121911]
11. Joshi, Kalpana S KS and 7 more authors. 2007-03 In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00. [PMID:17363486]
12. Squires, Matthew S MS and 7 more authors. 2009-02 Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. [PMID:19174555]
13. Cirstea, D D and 15 more authors. 2013-12 Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. [PMID:23807770]
14. Gelbert, Lawrence M LM and 16 more authors. 2014-10 Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. [PMID:24919854]
15. Paiva, Cody C and 8 more authors. 2015 Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells. [PMID:26606677]
16. Bisi, John E JE, Sorrentino, Jessica A JA, Roberts, Patrick J PJ, Tavares, Francis X FX and Strum, Jay C JC. 2016-05 Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression. [PMID:26826116]
17. Klaeger, Susan S and 47 more authors. 2017-12-01 The target landscape of clinical kinase drugs. [PMID:29191878]
18. Wang, Yan Y and 10 more authors. 2018-03-01 Design and synthesis of 4-(2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-7-yl)-N-(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine as a highly potent and selective cyclin-dependent kinases 4 and 6 inhibitors and the discovery of structure-activity relationships. [PMID:29429832]
19. Tear, Westley F and 16 more authors. 2020-01-23 Selectivity and Physicochemical Optimization of Repurposed Pyrazolo[1,5-b]pyridazines for the Treatment of Human African Trypanosomiasis. [PMID:31846577]
20. Wu, Tizhi and 6 more authors. 2020-11-25 Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update. [PMID:32866383]

6-(4-(6-((6-acetyl-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)hexanamide

Names and Identifiers

Alternative Forms

Associated Targets(Human)

Molecule Features

Drug Indications

Mechanisms of Action

Biocomponents

Calculated Properties

References

Source